SMAIO SA (ALSMA.PA) Stock Price, Quote, News and Overview
EPA:ALSMA - Euronext Paris - Matif - FR0014005I80 - Common Stock - Currency: EUR
ALSMA.PA Quote, Performance and Key Statistics
EPA:ALSMA (6/17/2025, 7:00:00 PM)
4.04
+0.24 (+6.32%)
The current stock price of ALSMA.PA is 4.04 EUR. In the past month the price increased by 4.12%. In the past year, price increased by 6.88%.
ALSMA.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABL.DE | ABBOTT LABORATORIES | 27.85 | 200.12B | ||
| 1ISRG.MI | INTUITIVE SURGICAL INC | 68.27 | 161.49B | ||
| IUI1.DE | INTUITIVE SURGICAL INC | 67.52 | 159.71B | ||
| BSX.DE | BOSTON SCIENTIFIC CORP | 37.94 | 130.78B | ||
| 2M6.DE | MEDTRONIC PLC | 15.79 | 96.22B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 20.15 | 51.36B | ||
| BOX.DE | BECTON DICKINSON AND CO | 12.19 | 42.56B | ||
| EWL.DE | EDWARDS LIFESCIENCES CORP | 28.51 | 37.63B | ||
| DC4.DE | DEXCOM INC | 50.15 | 28.12B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 14.18 | 18.40B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 14.18 | 18.39B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 13.97 | 18.13B |
Related stock screener links
About ALSMA.PA
Company Profile
S.M.A.I.O SA engages in the design, manufacture, and distribution of medical devices for the treatment of spinal pathologies. The company is headquartered in Saint-Priest, Auvergne-Rhone-Alpes. The company went IPO on 2022-04-06. The firm provides control on a surgical procedure to spine physician through a wide range of solutions like surgical plan/ i-plan, surgical procedure i-perform, outcome data/ i-check, and education/ i-learn. The company operates with the clinical data and imaging for specialists in spine surgery for transformation of the vertebral fusion. The company also offers spine surgeons a complete solution, consisting of software, implantable devices, associated services, and treat spinal pathologies requiring surgery. The company includes Kheiron Spinal Fixation System, a device that incorporates many implants, intended for the immobilization and stabilization of spinal segments as an adjunct to fusion of the thoracic, lumbar and/or sacral spine. The company also develops the Keops and Balance Analyzer 3D surgical planning and patient database management software.
Company Info
SMAIO SA
2 Place Berthe Morisot, Parc Technologique
Saint-Priest AUVERGNE-RHONE-ALPES FR
Employees: 43
Phone: 33469842302
SMAIO SA / ALSMA.PA FAQ
What is the stock price of SMAIO SA today?
The current stock price of ALSMA.PA is 4.04 EUR. The price increased by 6.32% in the last trading session.
What is the ticker symbol for SMAIO SA stock?
The exchange symbol of SMAIO SA is ALSMA and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ALSMA.PA stock listed?
ALSMA.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for SMAIO SA stock?
9 analysts have analysed ALSMA.PA and the average price target is 6.12 EUR. This implies a price increase of 51.49% is expected in the next year compared to the current price of 4.04. Check the SMAIO SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SMAIO SA worth?
SMAIO SA (ALSMA.PA) has a market capitalization of 22.83M EUR. This makes ALSMA.PA a Nano Cap stock.
How many employees does SMAIO SA have?
SMAIO SA (ALSMA.PA) currently has 43 employees.
What are the support and resistance levels for SMAIO SA (ALSMA.PA) stock?
SMAIO SA (ALSMA.PA) has a support level at 3.84. Check the full technical report for a detailed analysis of ALSMA.PA support and resistance levels.
Is SMAIO SA (ALSMA.PA) expected to grow?
The Revenue of SMAIO SA (ALSMA.PA) is expected to grow by 2.79% in the next year. Check the estimates tab for more information on the ALSMA.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SMAIO SA (ALSMA.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALSMA.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALSMA.PA, evaluating the profitability, health, valuation and growth aspects
- SMAIO SA (ALSMA.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SMAIO SA (ALSMA.PA) Sales and EPS estimates to see what analysts future expectations are.
- SMAIO SA (ALSMA.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SMAIO SA (ALSMA.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- SMAIO SA (ALSMA.PA) Stock Chart to make your own analysis
- SMAIO SA (ALSMA.PA) Latest news and press-releases to stay up to date.
Does SMAIO SA (ALSMA.PA) stock pay dividends?
ALSMA.PA does not pay a dividend.
What is the Price/Earnings (PE) ratio of SMAIO SA (ALSMA.PA)?
SMAIO SA (ALSMA.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.34).
ALSMA.PA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALSMA.PA. When comparing the yearly performance of all stocks, ALSMA.PA is one of the better performing stocks in the market, outperforming 83.41% of all stocks.
ALSMA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALSMA.PA. While ALSMA.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALSMA.PA Financial Highlights
Over the last trailing twelve months ALSMA.PA reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS decreased by -24.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.21% | ||
| ROE | -22.35% | ||
| Debt/Equity | 0.31 |
ALSMA.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ALSMA.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -70.21% and a revenue growth 2.79% for ALSMA.PA